ERAS — Erasca, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1761918 ·
Last close
$14.05
Market Cap
$4.37B
52W High
$24.28
52W Low
$8.70
ADV30
4,992,803
Next earnings
2026-05-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -37,911,000 | -183,440,000 | 461,234,000 | 47,256,000 | 67,706,000 |
| Dec 2025 | 0 | — | -32,604,000 | -29,092,000 | 396,154,000 | 73,805,000 | 70,983,000 |
| Sep 2025 | 0 | — | -32,546,000 | -30,612,000 | 420,401,000 | 70,230,000 | 72,515,000 |
| Jun 2025 | 0 | — | -30,625,000 | -33,876,000 | 445,386,000 | 66,143,000 | 73,128,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-91,283,000
Investing CF
$-177,670,000
Financing CF
$245,727,000
CapEx
$-159,581,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.93
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,075,649,000
Inventory
—
Receivables
—
ST Investments
$196,532,000
EBIT TTM
$-133,686,000
Pretax Income TTM
$-277,020,000
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -131,405,000 | -124,546,000 | 396,154,000 | 70,983,000 | — | -95,455,000 |
| Dec 2024 | 0 | -157,087,000 | -161,650,000 | 502,526,000 | 79,027,000 | — | -109,417,000 |
| Dec 2023 | 0 | -141,525,000 | -125,042,000 | 395,297,000 | 78,611,000 | — | -101,217,000 |
| Dec 2022 | 0 | -145,450,000 | -242,805,000 | 514,909,000 | 103,056,000 | — | -103,264,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.57
Max Pain — expiry 2026-06-18
max pain strike: $15.00 · spot: $14.43 · call oi: 9,303 · put oi: 7,227
Expected Move to 2026-06-18:
±$1.12
(7.80%) —
implied range
$13.31 –
$15.56
· ATM straddle on $15.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GIFLF | Grifols SA | $4.48B | $10.60 | — |
| DNTH | Dianthus Therapeutics, Inc. /DE/ | $4.49B | $82.07 | — |
| ORKA | Oruka Therapeutics, Inc. | $4.22B | $69.89 | — |
| INDV | Indivior Pharmaceuticals, Inc. | $4.55B | $38.48 | — |
| MANE | Veradermics, Inc | $4.01B | $96.07 | — |
News headlines (Yahoo Finance, 1h cache)
Erasca (ERAS) Receives Encouraging Expert Feedback on ERAS-0015 Clinical Trials
2026-06-11 10:20 · Yahoo
TNGX Stock Jumps 53% on Early Pancreatic Cancer Study Results
2026-06-09 16:44 · Yahoo
Erasca (ERAS) Is Down 13.4% After IP Challenge to ERAS-0015 Trade Secrets and Patents
2026-06-08 16:12 · Yahoo
Erasca Inc. (ERAS) Inspiring Confidence Through Commercial Collaborations
2026-06-05 15:55 · Yahoo
Erasca Sees More Balanced Outlook as Early RAS Data Support Clinical Activity, BofA Says
2026-06-04 14:49 · Yahoo
Here is Why Erasca (ERAS) is One of the Best Growth Stocks Under $20
2026-06-03 17:59 · Yahoo
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800%
2026-05-30 00:47 · Yahoo
Erasca to Present at the Jefferies Global Healthcare Conference
2026-05-27 12:00 · Yahoo
Erasca Patent Dispute Puts ERAS-0015 And Investment Case Under Scrutiny
2026-05-26 00:19 · Yahoo
Propanc Biopharma’s CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade
2026-05-20 12:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.